Symptomatic Dermographism in Practice: What APPs Should Know About a New Treatment Option

The approval of remibrutinib introduces a new treatment option for symptomatic dermographism and an opportunity for advanced practice providers to revisit recognition, assessment, and management of the chronic inducible urticaria subtype.

A patient reports developing itchy, raised welts wherever their skin is scratched, rubbed, or exposed to pressure. The lesions may disappear relatively quickly, but the cycle happens repeatedly—sometimes from something as routine as clothing rubbing against the skin.

For advanced practice providers (APPs), recognizing this pattern can be an important first step toward identifying symptomatic dermographism, a form of chronic inducible urticaria.

The recent FDA approval of remibrutinib (Rhapsido) has also changed the treatment conversation. The oral Bruton tyrosine kinase (BTK) inhibitor is now approved for adults with symptomatic dermographism who remain symptomatic despite H1 antihistamine treatment, providing the first FDA-approved treatment specifically indicated for these patients.

So, what should NPs and PAs know as this option enters clinical practice?

Recognizing Symptomatic Dermographism

Dermographism is characterized by the development of linear wheals following mechanical stimulation of the skin. However, the presence of dermographism alone does not necessarily mean a patient has symptomatic disease requiring treatment.

Patients with symptomatic dermographism experience accompanying symptoms such as pruritus and recurrent whealing following triggers including scratching, rubbing, or pressure.

For APPs evaluating patients with suspected urticaria, asking what happens immediately after the skin is scratched or rubbed, and how frequently those reactions interfere with everyday activities, can help distinguish the patient's experience and disease burden.

When Antihistamines Are Not Enough

Second-generation H1 antihistamines have traditionally formed the foundation of treatment for chronic inducible urticaria, including symptomatic dermographism.

However, some patients remain symptomatic despite antihistamine therapy.

That treatment gap is particularly relevant following the approval of remibrutinib, which is indicated for adults with symptomatic dermographism who remain symptomatic despite H1 antihistamine treatment.

For APPs, persistent symptoms despite appropriate antihistamine use may now prompt a different conversation about treatment escalation.

Where Remibrutinib Fits

Remibrutinib is an oral, highly selective BTK inhibitor designed to inhibit BTK-mediated signaling involved in mast cell activation and histamine release.

Its approval for symptomatic dermographism was supported by phase 3 data evaluating patients whose disease remained inadequately controlled with H1 antihistamines.

Rather than broadly suppressing the immune system, BTK inhibition targets signaling involved in the processes contributing to wheal and itch development.

Understanding that mechanism can help APPs explain to patients why the treatment differs from the antihistamines they may already have tried.

Turning the Approval Into a Patient Conversation

For patients who have lived with recurrent itching and whealing triggered by ordinary contact with their skin, symptomatic dermographism can affect clothing choices, physical activity, sleep, and other aspects of everyday life.

That makes symptom assessment an important part of follow-up.

APPs can ask patients not only whether wheals are still occurring, but how frequently symptoms develop, which triggers patients have begun avoiding, how disruptive the itching is, and whether the condition is affecting daily activities.

The availability of the first treatment specifically approved for symptomatic dermographism adds another option when those symptoms persist despite antihistamine therapy.

The APP Takeaway

The approval of remibrutinib represents more than the addition of another urticaria therapy. It creates a new treatment pathway specifically for adults with symptomatic dermographism whose symptoms persist despite H1 antihistamines.

For NPs and PAs, that makes recognizing the condition, assessing its real-world burden, and identifying patients who remain symptomatic on antihistamine therapy increasingly important.

As targeted therapies expand across dermatology, APPs will continue to play a central role in translating new treatment options into practical, individualized care.

References

1. Novartis receives FDA approval for Rhapsido (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU). News release. Novartis. September 30, 2025. Accessed October 8, 2026. https://www.globenewswire.com/news-release/2025/09/30/3159065/0/en/Novartis-receives-FDA-approval-for-Rhapsido-remibrutinib-the-only-oral-targeted-BTKi-treatment-for-chronic-spontaneous-urticaria-CSU.html
2. Remibrutinib meets primary endpoints in phase 3 trial for chronic inducible urticaria subtypes. Dermatology Times. February 18, 2026. Accessed October 8, 2026. https://www.dermatologytimes.com/view/remibrutinib-meets-primary-endpoints-in-phase-3-trial-for-chronic-inducible-urticaria-subtypes